BRAF and neoplasm: A combination of RAF, MEK, and ERK inhibitors effectively suppressed tumor growth in xenograft models derived from samples of both targeted therapy-naive and pre-treated patients with melanoma or lung cancer and BRAF V600E mutations [93].